Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App




Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021

SEKISUI Diagnostics (Burlington, MA, USA) displayed its point-of-care rapid diagnostics and clinical chemistry reagents at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. More...

This year’s 2021 AACC was held in partnership with the Canadian Society of Clinical Chemists (CSCC) at the Georgia World Congress Center in Atlanta, September 26-30. SEKISUI Diagnostics delivers differentiated products, instrument systems, and services that support the improvement of patient care worldwide. The company is a recognized leader in the development, manufacture, and supply of innovative clinical chemistry reagents and systems that enhance the clinical chemistry laboratory function. Over 1.7 billion tests are performed each year using the company’s products. With a broad line of >65 reagents including cardiovascular, diabetes, renal, liver, therapeutic drug, and specialty assays, SEKISUI is well-poised to meet individual needs.

At AACC 2021, SEKISUI displayed its OSOM rapid diagnostics that offers a variety of family and women’s health products, and services. These diagnostic tests allow healthcare professionals to cost effectively diagnose at the point-of-care in one visit, thus reducing labor and follow-up time while increasing patient satisfaction. The company also demonstrated its Acucy System that provides clinicians with flexibility in workflow and accurate, standardized results for improved patient care.

Also on display was SEKISUI’s FastPack IP System which is a fully automated quantitative immunoassay analyzer designed for use in any size physician office laboratory and provides results in 12 minutes or less with the push of a button. Offering real-time testing with a simple three-step process, the system enables healthcare professionals to diagnose, monitor, and adjust therapy in one patient visit.

Related Links:
SEKISUI Diagnostics 


New
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
New
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Clinical Chemistry Analyzer
Envoy 500+
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.